Precision Biosciences (DTIL) Cash from Investing Activities (2018 - 2026)
Precision Biosciences' (DTIL) quarterly Cash from Investing Activities came in at -$114000.0 in Q1 2026, up 63.69% year-on-year from -$69642.0 in Q1 2025, and up 64.92% on a QoQ basis from -$325000.0 in Q4 2025.
Precision Biosciences (DTIL) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 9 years of Cash from Investing Activities data on file, last reported at -$114000.0 in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 63.69% year-over-year to -$114000.0 in Q1 2026; TTM through Mar 2026 was -$434000.0, a 13.72% increase from a year earlier, with the FY2025 full-year figure at -$634000.0, down 194.88% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$114000.0, up from -$325000.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for DTIL reached as high as $7.6 million in Q3 2023 and fell as low as -$1.1 million in Q3 2022.
- Historically, Cash from Investing Activities has averaged $91000.0 across 5 years, with a median of -$114000.0 in 2026.
- Across the five-year window, Cash from Investing Activities soared 793.94% in 2023 and slumped 1107.69% in 2025, its largest moves.
- Year by year, Cash from Investing Activities stood at -$632000.0 in 2022, then jumped by 106.65% to $42000.0 in 2023, then tumbled by 330.95% to -$97000.0 in 2024, then tumbled by 235.05% to -$325000.0 in 2025, then soared by 64.92% to -$114000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$114000.0 in Q1 2026, -$325000.0 in Q4 2025, and $17000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Precision Biosciences | 178.85 Mn | 150.56 Mn | - | -114,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -114,000.00 |
| Mar 31, 2026 | -114,000.00 |
| Dec 31, 2025 | -325,000.00 |
| Dec 31, 2025 | -325,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Jun 30, 2025 | -12,000.00 |
| Jun 30, 2025 | -12,000.00 |
| Mar 31, 2025 | -314,000.00 |
| Mar 31, 2025 | -314,000.00 |
| Dec 31, 2024 | -97,000.00 |
| Dec 31, 2024 | -97,000.00 |
| Sep 30, 2024 | -64,000.00 |
| Sep 30, 2024 | -64,000.00 |
| Jun 30, 2024 | -28,000.00 |
| Jun 30, 2024 | -28,000.00 |
| Mar 31, 2024 | -26,000.00 |
| Mar 31, 2024 | -26,000.00 |
| Dec 31, 2023 | 42,000.00 |
| Dec 31, 2023 | 42,000.00 |